x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Aug 18, 2016 6:33 EST

Pro-GeneX, LLC – a marketer of pharmacogenetic testing: Our combined genetic testing/consulting services help Acute-care and Long Term Post Acute Care operators maximize the information from test results

iCrowdNewswire - Aug 18, 2016

Pro-GeneX, LLC Logo

Pro-GeneX, LLC

Atlanta, GA 30308, US
Healthcare
www.Pro-GeneX.com

Pro-Genex is a marketer of pharmacogenetic testing based at Georgia Tech, in Atlanta, Georgia. Our combined genetic testing/consulting services help Acute-care and Long Term Post Acute Care operators maximize the information from test results.

Nearly 100,000 people die annually due to Adverse Drug Events/Adverse Drug Reactions. More than 1.5 million are hospitalized and the annual cost for treating these avoidable injuries exceeds $180 billion USD. The APA estimates that more than 10% of patients are taking at least one drug that isn’t working for them. The need exists to provide an immediate solution to the rising number of patient injuries. Long Term Care Operators and healthcare systems are under CMS mandates to improve in a large number of Core Quality Measures (CQMs) and other such metrics. To maximize revenues and minimize penalties it is also important to reduce the time required to bring patients to a high level of therapeutic benefit related to their medications.

OUR PRODUCT
Our genetic test products evaluate the Cytochrome P450 system in the body. This process is called Pharmacogenetic testing (PGX). The test determines if the genes related to this system are causing the body to express normal amounts of enzymes used in the metabolism of drugs. Abnormalities in this system are common, resulting in non-standard enzyme expression.
Pharmacogenetic testing holds the promise of assisting physicians and patients in selecting the right medication and the right dosage level at the outset of treatment, minimizing the risk of adverse drug events (ADRs) and maximizing outcomes. By knowing an individual’s specific metabolism of specific medications, physicians can make adjustments to dosage early on, or even choose a different medication. The result is a reduction of costs and an increase in patient satisfaction which can help drive additional revenue. The tests have reimbursement from CMS and most private insurers.

We are the only company of our kind in the industry that provides census-level data from our testing results to healthcare networks, assisting in documenting positive change across important metrics and demonstrating meaningful use to drive larger reimbursement rates from CMS.

 

Products / Services

Pharmacogenetic Testing

Our genetic test products evaluate the Cytochrome P450 system in the body. This process is called Pharmacogenetic testing (PGX). The test determines if the genes related to this system are causing the body to express normal amounts of enzymes used in the metabolism of drugs. Abnormalities in this system are common, resulting in non-standard enzyme expression.
Pharmacogenetic testing holds the promise of assisting physicians and patients in selecting the right medication and the right dosage level at the outset of treatment, minimizing the risk of adverse drug events (ADRs) and maximizing outcomes. By knowing an individual’s specific metabolism of specific medications, physicians can make adjustments to dosage early on, or even choose a different medication.. The tests are FDA approved and have reimbursement from CMS and most private insurers. Our lab handles all billing so there is no added administrative burden to the client.

 

Management

Chief Executive Officer
Robert Rupard

Robert RupardFrom 2010 until early 2014 he served as Chief Operating Officer for Sensiotec, Inc., a Georgia Tech-based medical device firm. He was responsible for managing all research, implementation, deployment and training services for beta sites, clinical trials and managing day-to-day operations.

Prior to that, he was Founder and Chief Executive Officer / Director of Operations for Wings Air, a 75-employee, regional commuter airline that operated 10 aircraft in five states, provided scheduled service into Hartsfield Jackson International Airport, and conducted over 125 daily operations seven days a week. He was responsible for initiating gate operations at Hartsfield Jackson Airport, successfully negotiating changes in the airport security plan and establishing a new record for regulatory approval and airline conversion in the commuter industry, achieving commuter airline status with the Federal Aviation Administration and the U.S. Department of Transportation in less than 100 days.

Summary

Prior Year Revenue Current Year Revenue Next Year Revenue

 

Company Age Employees Sub-Industry
2 years 4 Medical Laboratories & Research

 

Company Type Stock Exchange Stock Symbol
Privately-Held

 

Contact Information:

Robert Rupard

View Related News >
support